Exicure has developed a patent for liposomal particles with unique properties, including increased stability and efficient cell entry without cationic agents. These spherical particles, containing oligonucleotides, offer a non-toxic delivery platform for gene regulation in various therapies, presenting an alternative to metal core spherical nucleic acids. GlobalData’s report on Exicure gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Exicure Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Exicure, Nanorobotics was a key innovation area identified from patents. Exicure's grant share as of February 2024 was 24%. Grant share is based on the ratio of number of grants to total number of patents.

Liposomal particles for gene regulation with spherical geometry

Source: United States Patent and Trademark Office (USPTO). Credit: Exicure Inc

A recently granted patent (Publication Number: US11883535B2) discloses a liposomal particle with a substantially spherical geometry, featuring a lipid bilayer containing a variety of lipid groups and single-stranded oligonucleotides that are inhibitory RNA or antisense DNA. These oligonucleotides are attached to the surface of the liposomal particle, with each oligonucleotide being an oligonucleotide-lipid conjugate containing a lipophilic tethered group anchored into the external side of the lipid bilayer. The hybridization between the oligonucleotide and the polynucleotide encoding a gene product occurs over a length of the polynucleotide with a degree of complementarity sufficient to inhibit the expression of the gene product. The diameter of the liposomal particle is specified to be less than or equal to 50 nanometers.

Furthermore, the patent details the composition of the lipid bilayer, which includes lipids such as phosphatidylcholine, phosphatidylglycerol, and phosphatidylethanolamine. The lipophilic tethered group mentioned in the claims comprises tocopherol or cholesterol, with specific tocopherol derivatives like alpha-tocopherol, beta-tocopherol, gamma-tocopherol, and delta-tocopherol being highlighted. The patent also mentions the presence of modified oligonucleotides with phosphorothioate linkages and specifies the number of oligonucleotides present in the liposomal particle, ranging from about 10 to 80. Additionally, the patent discusses the formation of a plurality of liposomal particles with a mean diameter of less than or equal to 50 nanometers, emphasizing the potential applications of these particles in various fields.

To know more about GlobalData’s detailed insights on Exicure, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies